Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model

Annals of Neurology

Volumn 52, Issue 4, 2002, Pages 503-506

  Collins, Steven J ^a   Lewis, Victoria ^a   Brazier, Marcus ^a   Hill, Andrew F ^a   Fletcher, Ashley ^a   Masters, Colin L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEPACRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; CELL CULTURE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL INFECTION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT FAILURE;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; MICE; MICE, INBRED BALB C; QUINACRINE; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0036791880     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10336     Document Type: Article

References (18)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95: 13363-13383.
2. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutafeldt-Jakob disease in the UK. Lancet 1996;347: 921-925.
3. D'Aignaux J, Cousens SN, Smith P. Predictability of the UK variant Creutzfeldt-Jakob disease epidemic. Science 2001;294: 1729-1731.
4. Valleron A-J, Boelle P-Y, Will R, Cesbron J-Y. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001;294: 1726-1728.
5. Priola S, Raines A, Caughey WS. Porphyrin and phthalocyanine anti-scrapie compounds. Science 2000;287:1503-1506.
6. Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997;276:1119-1122.
7. Xi YG, Ingrosso L, Ladogana A, et al. Amphotericin B treatment dissociates in vivo replication of the srcapie agent from PrP accumulation. Nature 1992;356:598-601.
8. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984;65:1325-1330.
9. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 1986;30:409-413.
10. Doh-ura K, Iwaki, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-4897.
11. Supattapone S, Nguyen H-O, Cohen F, et al. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA 1999;96:14529-14534.
12. Caughey B, Raymond G. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 1993;67:643-650.
13. Korth C, May BC, Cohen F, Prusiner SB. Acridine and phenothiazine derivatives as phamacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-9841.
14. Love R. Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet 2001;358:563.
15. Caughey B, Race R. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 1992;59:768-771.
16. Caughey B, Ernst D, Race R. Congo red inhibition of scrapie agent replication. J Virol 1993;67:6270-6272.
17. Diringer H, Ehlers B. Chemoprophylaxis of scrapie in mice. J Gen Virol 1991;72:457-460.
18. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 1998;95: 12117-12122.